BRCA2 and Familial prostate cancer: Taken together, these results demonstrate that BRCA2 levels modulate the sensitivity of prostate cancer cells to 6-TG to a similar extent as olaparib and that 6-TG treatment decreases the expression of AR independently on BRCA2.